Publications
Oligopeptide
permease A5 modulates vertebrate host-specific adaptation of
Borrelia burgdorferi.
Raju BV, Esteve-Gassent MD, Karna SL, Miller CL,
Van Laar TA, Seshu J.
Infect Immun. 2011 Aug;79(8):3407-20. Epub 2011 May
31.PMID:21628523
CsrA
modulates levels of lipoproteins and key regulators of gene
expression critical for pathogenic mechanisms of Borrelia
burgdorferi.
Karna SL, Sanjuan E, Esteve-Gassent MD, Miller
CL, Maruskova M, Seshu J.
Infect Immun. 2011 Feb;79(2):732-44. Epub 2010 Nov 15.
PMID:21078860
Overexpression
of CsrA (BB0184) alters the morphology and antigen profiles of
Borrelia burgdorferi.
Sanjuan E, Esteve-Gassent MD, Maruskova M, Seshu
J.Infect Immun. 2009 Nov;77(11):5149-62. Epub 2009 Sep 8.
PMID:19737901
sodA is
essential for virulence of Borrelia burgdorferi in the murine model
of Lyme disease.
Esteve-Gassent MD, Elliott NL, Seshu J. Mol
Microbiol. 2009 Feb;71(3):594-612. Epub 2008 Nov 24.
PMID:19040638
Role of
the BBA64 locus of Borrelia burgdorferi in early stages of
infectivity in a murine model of Lyme disease.
Maruskova M, Esteve-Gassent MD, Sexton VL, Seshu
J. Infect Immun. 2008 Jan;76(1):391-402. Epub 2007 Nov 5.
PMID:17984202
Inactivation of
the fibronectin-binding adhesin gene bbk32 significantly attenuates
the infectivity potential of Borrelia burgdorferi.
Seshu J, Esteve-Gassent MD, Labandeira-Rey M, Kim
JH, Trzeciakowski JP, Höök M, Skare JT. Mol Microbiol. 2006
Mar;59(5):1591-601. PMID:16468997
The eel
immune system: present knowledge and the need for
research.
Nielsen ME, Esteve-Gassent MD. J Fish Dis. 2006
Feb;29(2):65-78. Review. PMID:16436117
Immunogenic
antigens of the eel pathogen Vibrio vulnificus serovar E.
Esteve-Gassent MD, Amaro C. Fish Shellfish
Immunol. 2004 Sep;17(3):277-91. PMID: 15276607
Vaccination of market-size eels against vibriosis due to Vibrio
vulnificus serovar E
Esteve-Gassent, MD, R. Barrera, C.
Amaro. Aquaculture, Volume 241, Issues 1-4, 26 November 2004,
Pages 9-19
Efficacy
of a bivalent vaccine against eel diseases caused by Vibrio
vulnificus after its administration by four different
routes.
Esteve-Gassent MD, Fouz B, Amaro C. Fish
Shellfish Immunol. 2004 Feb;16(2):93-105. PMID: 15123314
Efficacy of oral reimmunisation after immersion vaccination against
Vibrio vulnificus in farmed European eels
Aquaculture, Volume 231, Issues 1-4, 5 March 2004, Pages 9-22
The
kinetics of antibody production in mucus and serum of European eel
(Anguilla anguilla L.) after vaccination against Vibrio
vulnificus: development of a new method for antibody quantification
in skin mucus.
Esteve-Gassent MD, Nielsen ME, Amaro C. Fish
Shellfish Immunol. 2003 Jul;15(1):51-61. PMID:12787687
Field
testing of a vaccine against eel diseases caused by Vibrio
vulnificus.
Fouz B, Esteve-Gassent MD, Barrera R, Larsen JL,
Nielsen ME, Amaro C. Dis Aquat Organ. 2001 Aug 2;45(3):183-9.
PMID:11558727
Vibrio harveyi causes
disease in seahorse, Hippocampus sp.
Alcaide, E., Gil-Sanz, C., Sanjuán, E., Esteve,
D., Amaro, C., Silveira, L. (2001) Journal of fish Disease
24, 311-313.
Design and development
of a vaccine against eel vibriosis caused by Vibrio
vulnificus serovar E (or biotype 2) applied to intensive
culture facilities
MAPYA (2001) Amaro, C., Fouz, B., Collado, R.,
Esteve-Gassent, D., Marco-Noales, E., Esteve, C.,
Barrera, R., Alcaide, E.